Background Thrombosis is a unique complication of coronavirus disease 2019 (COVID-19).
Although antiphospholipid antibodies (aPL) are detected in COVID-19 patients, their clinical …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a
profound hypercoagulable state and often develop coagulopathy which leads to organ …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a
profound hypercoagulable state and often develop coagulopathy which leads to organ …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

We sought to determine the prevalence of antiphospholipid antibodies (aPLs) and their
correlation with COVID-19 severity (in terms of clinical and laboratory parameters) in …

Background The significance of antiphospholipid antibodies (aPL) in COVID-19 remains
uncertain. Objectives We determined whether aPL are associated with COVID-19 and/or …

Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombotic arterial and
venous occlusions. At the same time, lung histopathology often reveals fibrin-based …

Background and objectives COVID-19-associated coagulopathy, shown to increase the risk
for the occurrence of thromboses and microthromboses, displays phenotypic features of the …

Currently, there are few data on Antiphospholipid antibodies (aPL Ab) in COVID-19 and it is
unclear if they represent an epiphenomenon or are involved in pathogenesis of COVID-19 …

Background: COVID-19 clinical features include a hypercoagulable state that resembles the
antiphospholipid syndrome (APS), a disease characterized by thrombosis and presence of …